Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an average annual return of 12.68%. Currently, Vertex Pharmaceuticals has a ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

The upcoming year is set to focus on the launch of Vanza and the acute pain product, alongside progressing ... underpin Yee’s positive outlook on Vertex Pharmaceuticals. In another report ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc ... driven by cost reductions and a ...

Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... is expected to become a multi-billion dollar product if approved. It works by blocking pain signals at their origin before they ...

Vertex Pharmaceuticals Inc. notched two FDA victories ... blockbuster CF drug, helping drive its product revenue to $9.87 billion last year. Alyftrek is approved for CF patients 6 years and ...